Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMETHYST LTE: long-term extension study of litifilimab in subacute and/or chronic cutaneous lupus erythematosus
CTR20251514Phase 3Active
- Sponsor
- Biogen
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of litifilimab in cutaneous lupus erythematosus (CLE), subacute cutaneous lupus erythematosus (SCLE), discoid lupus erythematosus (DLE), sponsored by Biogen. Started Sep 2025; status: active.
02
Drugs
litifilimab
03
Conditions
cutaneous lupus erythematosus (CLE)subacute cutaneous lupus erythematosus (SCLE)discoid lupus erythematosus (DLE)
Beyond the preview
Go deeper on CTR20251514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251514.